Drug Discovery

Gilead, Renown Institute for Health Innovation announce collaboration to advance understanding of NASH

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease.

Jazz Pharmaceuticals acquires pre-clinical pan-RAF inhibitor program from Redx Pharma

Jazz Pharmaceuticals has signed a definitive agreement for the acquisition of Redx Pharma's pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors.

Celsius Therapeutics signs collaboration agreement with Janssen to identify response biomarkers for ulcerative colitis

Celsius Therapeutics, a company focused on the discovery and development of precision therapeutics for patients with autoimmune diseases and cancer, today announced a collaboration with Janssen Biotech, Inc.

Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma

Altimmune, a clinical-stage biopharmaceutical company, has agreed to acquire Presidio Partners portfolio company Spitfire Pharma in a deal valued at around $93m (£74.5m).

Lyndra Therapeutics and Gilead Sciences to collaborate on development of ultra-long-acting HIV therapeutics

Lyndra Therapeutics, the company making daily pills a thing of the past, has announced a partnership with Gilead Sciences, Inc. to develop and commercialize ultra-long-acting oral HIV therapies.

MorphoSys secures option to license Vivoryon’s QPCTL inhibitors for cancer

MorphoSys has signed an agreement with Vivoryon Therapeutics to obtain an exclusive option to license the latter’s small molecule glutaminyl-peptide cyclotransferase-like (QPCTL) inhibitors for developing oncology treatments.

PhoreMost, inStem enter structural biology alliance

PhoreMost, the UK-based biopharmaceutical company, has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India.

Boehringer Ingelheim, Yuhan sign £689m NASH license deal

Boehringer Ingelheim has signed a collaboration and license agreement with South Korean pharma company Yuhan, potentially worth up to $870m (£689m), for the latter’s fusion protein for the treatment of Nonalcoholic Steatohepatitis (NASH) and related liver diseases.

Rafael Pharmaceuticals, Ono Pharmaceutical to accelerate clinical development of cancer drug candidate CPI-613

Rafael Pharmaceuticals, a leader in the growing field of cancer metabolism-based therapeutics, has entered into an out-licensing agreement with Ono Pharmaceutical, a pharmaceutical company committed to creating innovative medicines.